» Authors » Nubia Boechat

Nubia Boechat

Explore the profile of Nubia Boechat including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 88
Citations 708
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
de Jesus Hiller N, Pimenta Salles J, Villas Boas Hoelz L, Costa Zorzanelli B, Amorim Fernandes T, Boechat N, et al.
Biomed Pharmacother . 2025 Feb; 185:117945. PMID: 40015050
P2X7 purinergic receptor (P2X7R) is a promising target for the development of new anti-inflammatory therapies. This can be inferred from the number of pharmaceutical patents aimed at inhibitors of this...
2.
Nascimento M, Moura S, Parra L, Vasconcellos V, Costa G, Leite D, et al.
Pharmaceuticals (Basel) . 2024 Oct; 17(10). PMID: 39459001
The primary treatment for chronic myeloid leukemia (CML) involves first- and second-generation tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, bosutinib, and dasatinib. However, these medications are ineffective against mutations...
3.
Ramos L, de Souza K, Barbosa J, Salomao K, Sales Junior P, Pereira V, et al.
Bioorg Med Chem Lett . 2024 Jul; 110:129876. PMID: 38964519
In this study, we present the design, synthesis, and cytotoxic evaluation of a series of benzimidazole N-acylhydrazones against strains of T. cruzi (Y and Tulahuen) and Leishmania species (L. amazonensis...
4.
Soeiro M, Sales-Junior P, Alves Pereira V, Vannier-Santos M, Murta S, Silvestre de Sousa A, et al.
Mem Inst Oswaldo Cruz . 2024 Jul; 119:e240057. PMID: 38958341
Chagas disease is a tropical neglected disease that affects millions of people worldwide, still demanding a more effective and safer therapy, especially in its chronic phase which lacks a treatment...
5.
Ramos L, de Souza K, Ademar Sales Junior P, Camara C, Castelo-Branco F, Boechat N, et al.
Acta Trop . 2024 May; 256:107264. PMID: 38806090
Chagas disease (CD), caused by the flagellated protozoan Trypanosoma cruzi (T. cruzi), affects approximately 7 million people worldwide and is endemic in Latin America, especially among socioeconomically disadvantaged populations. Since...
6.
Pitombeira M, Junior P, Murta S, Romanha A, Luccas P, Nonato M, et al.
Arch Pharm (Weinheim) . 2024 Apr; 357(7):e2400059. PMID: 38627301
Chagas disease is a neglected tropical parasitic disease caused by the protozoan Trypanosoma cruzi. Worldwide, an estimated 8 million people are infected with T. cruzi, causing more than 10,000 deaths...
7.
de Azevedo L, Leite D, de Oliveira A, Junior F, Dantas R, Bastos M, et al.
Arch Pharm (Weinheim) . 2024 Apr; 357(8):e2400029. PMID: 38627294
Imatinib mesylate was the first representative BCR-ABL1 tyrosine kinase inhibitor (TKI) class for the treatment of chronic myeloid leukemia. Despite the revolution promoted by TKIs in the treatment of this...
8.
Feitosa L, Franca R, Ferreira M, Aguiar A, de Souza G, Maluf S, et al.
Eur J Med Chem . 2024 Jan; 267():116163. PMID: 38290351
The World Health Organization (WHO) estimated that there were 247 million malaria cases in 2021 worldwide, representing an increase in 2 million cases compared to 2020. The urgent need for...
9.
Leite D, Campanico A, Costa P, Correa I, da Costa L, Bastos M, et al.
Arch Pharm (Weinheim) . 2023 Nov; 357(2):e2300560. PMID: 38032154
Tuberculosis (TB) disease, caused by Mycobacterium tuberculosis (Mtb) is the leading cause of death among people with human immunodeficiency virus (HIV) infection. No dual-target drug is currently being used to...
10.
Menozzi C, Franca R, Luccas P, Baptista M, Amorim Fernandes T, Villas Boas Hoelz L, et al.
Molecules . 2023 Nov; 28(22). PMID: 38005183
Chagas disease (CD), which is caused by and was discovered more than 100 years ago, remains the leading cause of death from parasitic diseases in the Americas. As a curative...